Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

eve that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

 

 Pharmacyclics, Inc.Condensed Consolidated Balance Sheets(unaudited; in thousands)Jun. 30,Dec. 31,20132012AssetsCash, cash equivalents and marketable securities 1$ 504,984$ 317,114Other current assets 248,16829,378Total current assets553,152346,492Property and equipment, net14,2176,403Other assets3,2762,234Total assets$ 570,645$ 355,129Liabilities and Stockholders' EquityDeferred revenue - current portion$
7,680$
8,139Other current liabilities44,69721,118Total current liabilities52,37729,257Deferred revenue - non-current portion55,60562,562Deferred rent800784Total liabilities108,78292,603Stockholders' equity461,863262,526Total liabilities and stockholders' equity$ 570,645$ 355,1291Marketable securities$   10,830$
9,6812As of June 30, 2013 and December 31, 2012, Other current assets includes $37.3 million and $26.6 million, respectively, due to the Company from Janssen under the collaboration and license agreement. Pharmacyclics, Inc.Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedJun. 30, Jun. 30,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that James ... has been elected to the Company,s Board of Directors, ... Anderson , Executive Chairman of CryoLife, stated, "Since joining the ... excellent leader who is well positioned to maximize CryoLife,s ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... approved Makena (hydroxyprogesterone caproate) in February 2011 for the ... women who have had at least one prior preterm ... version of the active ingredient of Makena has been ... a pharmacist who compounded the drug.  In March 2011, ...
... Covance Inc. (NYSE: CVD ) today announced ... on Thursday, November 10, 2011 at 3:00 p.m. (ET).  Investors ... www.covance.com .  In order to register and download any necessary ... with headquarters in Princeton, New Jersey, is one of the ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter , ... in vitro fertilization (IVF) are only about half as likely ... reproduction technique, new research indicates, and the racial disparity persists ... about 31 percent of white patients became pregnant after IVF, ... more than 4,000 IVF cycles over two years to tease ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... of abuse by intimate partners have significantly higher health ... of such abuse, according to a study conducted at ... higher costs and utilization continued long after the abuse ... of Washington (UW), and the Harborview Injury Prevention and ...
... how some passengers describe it.// , They ... were infected with a stomach flu-causing bug; norovirus aboard the ... This virus causes a contagious gastric illness, gastroenteritis that leaves ... , The liner’s owner Cunard Line notified the ...
... that neurologists believe will help in the management of epilepsy. ... New York carried out a study that showed that some ... occur. The findings were published in Neurology, the scientific journal ... Haut. ,Haut's team studied 71 adult patients ...
... and Forests has called for an action plan and ... National Workshop// on ‘Human - Leopard Conflict Management’ here ... need to have a re-look at our existing strategies ... one of the challenging issues facing wildlife managers in ...
... Parliament's health committee is all set to tighten the ... ,Three days of public hearing starting on Jan 23, ... organizations will make submissions before the committee. ... and the sponsorship of sports and other popular events ...
... (VBI) Assistant Professor Biswarup Mukhopadhyay has provided important ... diabetics in the// December 22, 2006, Journal of ... time help researchers to identify potential targets for ... fully eliminate, the body's overproduction of glucose. ...
Cached Medicine News:Health News:Health Care Costs - Significant for Abused Women 2Health News:When Epilepsy Patients Play Soothsayers 2Health News:VBI Provides Potential Targets to Diabetes Therapeutics 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: